Press Releases<< Back
Genomic Health Advances Liquid Biopsy Pipeline, Shows Ability to Accurately Monitor Urine for Presence of Bladder Cancer
"A non-invasive, urine-based test for monitoring patients for disease recurrence can improve bladder cancer patient care by optimizing the use of cystoscopies," said
It is estimated that early-stage bladder cancer recurs in only 10 to 15 percent of patients in the first year, and in more than half of patients over time. However, approximately one-third of all cystoscopies - a procedure using a thin instrument equipped with a camera and light to look at the inside of the bladder - generate false positive results.
"Building on the positive results from our previous, exploratory whole genome sequencing, here, we narrowed down our analysis to specific bladder cancer-related genomic regions to enable both accurate and cost-efficient detection of bladder cancer from urine," said
These new results, combined with an upcoming presentation of more detailed proof-of-concept study results at the
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the value and benefits of urine-based monitoring of bladder cancer patients; the expectation that the test results could enable a urine-based test for monitoring bladder cancer recurrence in early-stage patients, and the potential benefits of such a test; and the company's belief that the study results demonstrate continued progress toward development of non-invasive tests for individualized treatment at various stages of disease. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: the risks and uncertainties associated with the regulation of the company's tests; the results of clinical studies; the applicability of clinical study results to actual outcomes; the company's ability to develop and commercialize new tests, including tests based on liquid biopsy; the risk that the company may not obtain or maintain sufficient levels of reimbursement, domestically or abroad, for its existing tests and any future tests it may develop; the risks of competition; unanticipated costs or delays in research and development efforts; and the other risks set forth in the company's filings with the Securities and Exchange Commission, including the risks set forth in the company's quarterly report on Form 10-Q for the quarter ended March 31, 2015. These forward-looking statements speak only as of the date hereof. Genomic Health disclaims any obligation to update these forward-looking statement.
NOTE: The Genomic Health logo, Oncotype, Oncotype DX, Recurrence Score, and DCIS Score are trademarks or registered trademarks of Genomic Health, Inc. All other trademarks and service marks are the property of their respective owners.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/genomic-health-advances-liquid-biopsy-pipeline-shows-ability-to-accurately-monitor-urine-for-presence-of-bladder-cancer-300084563.html
News Provided by Acquire Media